Central Alerting System
View Alert

Originator: National Patient Safety Alert - DHSC

Issue date: 28-Sep-2023 14:13:31

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • Territorial CMOs in Northern Ireland, Scotland & Wales

Action category: Action

Title: Shortage of verteporfin 15mg powder for solution for injection

Broadcast content:

Verteporfin is indicated for the treatment of adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or adults with subfoveal choroidal neovascularisation secondary to pathological myopia. Verteporfin is also used in the treatment of ocular cancer in specialist centres.

Verteporfin is used off-label for the management of central serous retinopathy with photodynamic therapy.

Verteporfin has been in short supply globally since late 2020 due to capacity constraints at the manufacturing site. The issue is not expected to resolve until the middle of 2024.

This National Patient Safety Alert provides further background and clinical information and actions for providers.

Additional information: This alert is not relevant to primary care.

Alert reference: NatPSA/2023/012/DHSC

Action underway deadline: 02-Oct-2023

Action complete deadline: 20-Oct-2023


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency